Mio-Aas (Acetylsalicylic Acid)

Acetylsalicylic Acid, the active ingredient in Mio-Aas, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral dosage form for oral use. It treats pain, fever, inflammation and helps prevent arterial thrombosis in adult patients. GNH USA supplies Mio-Aas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mio-Aas belongs to the NSAID class and acts on the cyclo‑oxygenase pathway to relieve several common conditions. - Pain relief: reduces mild to moderate pain by inhibiting prostaglandin synthesis. - Fever reduction: lowers elevated body temperature through central thermoregulatory effects. - Inflammation reduction: diminishes swelling and redness by decreasing inflammatory mediators. - Prevention of arterial thrombosis: provides antiplatelet activity that lowers the risk of clot formation in cardiovascular disease.

Mio-Aas may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastro‑intestinal discomfort: nausea, dyspepsia or heartburn. - Abdominal pain or mild stomach upset. - Increased bleeding tendency, such as easy bruising or nosebleeds. - Skin rash or mild itching.

Serious or Rare Side Effects: - Gastro‑intestinal ulceration or hemorrhage. - Severe allergic reactions, including anaphylaxis or Stevens‑Johnson syndrome. - Renal impairment or acute kidney injury. - Hepatic dysfunction or elevated liver enzymes. - Reye's syndrome in children following viral illness.

Before using Mio-Aas, consider the following safety measures. - Assess bleeding risk: avoid in patients with active ulcers or recent surgery. - Avoid in known aspirin‑sensitive asthma or allergic reactions. - Use caution in renal impairment: monitor kidney function regularly. - Monitor in patients taking anticoagulants or other NSAIDs for additive bleeding risk. - Do not combine with alcohol or other gastric irritants without medical advice. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mio-Aas can interact with several medication classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Anticoagulants such as warfarin: increased risk of serious bleeding. - Other NSAIDs or cyclo‑oxygenase inhibitors: additive gastrointestinal toxicity. - Corticosteroids: heightened ulcer risk. - Selective serotonin reuptake inhibitors (SSRIs): enhanced bleeding tendency. - Lithium: aspirin may raise lithium serum levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in antihypertensive effect. - Diuretics: may impair renal function when combined. - Methotrexate: aspirin can decrease clearance, raising toxicity. - Oral hypoglycemics: potential alteration of blood glucose control. - Allopurinol or other uric‑acid‑lowering agents: risk of hypersensitivity reactions.